Clinical Trial: A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719348) titled 'A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies' on July 08.

Brief Summary: The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substud...